Dianthus Therapeutics Hits New 1-Year High After Analyst Upgrade

Biotech firm's stock surges on positive clinical trial news and bullish analyst calls

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Shares of Dianthus Therapeutics (NASDAQ:DNTH) reached a new 52-week high after the company received positive analyst coverage, including a price target increase from $47 to $130 by HC Wainwright. The rally was driven by Dianthus' announcement of an early "GO" decision in its Phase 3 CAPTIVATE CIDP trial, a material clinical de-risking event that prompted several analyst upgrades and price target increases.

Why it matters

Dianthus Therapeutics is a clinical-stage biotech company developing complement therapeutics for severe autoimmune and inflammatory diseases. The positive trial news and analyst upgrades signal growing investor confidence in the company's pipeline and potential to bring new treatments to market.

The details

In the Phase 3 CAPTIVATE CIDP trial, Dianthus' interim responder analysis met the company's "GO" criteria, allowing it to proceed with the 300mg subcutaneous every two weeks dose. This was seen as a major de-risking event by analysts, who subsequently raised their price targets on the stock. HC Wainwright upgraded the stock to "buy" and increased its price target from $47 to $130, while Truist raised its target from $63 to $110, also maintaining a "buy" rating.

  • On March 10, 2026, Dianthus Therapeutics shares hit a new 52-week high of $84.86.
  • On March 9, 2026, Dianthus reported Q4 earnings that missed consensus estimates.

The players

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases.

HC Wainwright

An investment bank that raised its price target on Dianthus Therapeutics from $47 to $130 and maintained a "buy" rating on the stock.

Truist Financial

A financial services company that raised its price target on Dianthus Therapeutics from $63 to $110 and maintained a "buy" rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.